MWM
CPRX

Mission Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Mission Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
11,121
+3
+0% +$71 0.01% 635
2025
Q4 		$259K Buy
11,118
+300
+3% +$6.68K 0.01% 638
2025
Q3 		$213K Buy
10,818
+198
+2% +$4.07K ﹤0.01% 669
2025
Q2 		$230K Buy
10,620
+510
+5% +$12K ﹤0.01% 630
2025
Q1 		$245K Buy
10,110
+10
+0.1% +$225 0.01% 596
2024
Q4 		$211K Buy
+10,100
New +$217K ﹤0.01% 622

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mission Wealth Management's CPRX Position: Q1 2026 in Review

Mission Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 0.03% in Q1 2026, buying an estimated $71 and bringing the position to 11,121 shares worth $275K. The position accounts for 0.01% of the portfolio, ranked #635.

Mission Wealth Management first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Mission Wealth Management held 11,121 shares of Catalyst Pharmaceutical worth $275K as of Q1 2026.
  • Mission Wealth Management bought 3 Catalyst Pharmaceutical shares in Q1 2026, an estimated $71.
  • Catalyst Pharmaceutical made up 0.01% of Mission Wealth Management's portfolio in Q1 2026, its #635 holding.
  • Mission Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.